Safe and effective administration of BCG for bladder carcinoma in situ after umbilical cord blood stem cell transplantation.

Magaribuchi, Toshihiro; Akamatsu, Shusuke; Kobayashi, Takashi; Kawabata, Hiroshi; Yamasaki, Toshinari; Inoue, Takahiro; Ogawa, Osamu

Magaribuchi, Toshihiro; Akamatsu, Shusuke; Kobayashi, Takashi; Kawabata, Hiroshi; Yamasaki, Toshinari; Inoue, Takahiro; Ogawa, Osamu.

Afiliação

Magaribuchi T; Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Akamatsu S; Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Kobayashi T; Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Kawabata H; Department of Hematology and Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Yamasaki T; Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Inoue T; Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Ogawa O; Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Transpl Infect Dis ; 19(6)2017 Dec.

Article em En | MEDLINE | ID: mdl-28796929

ABSTRACT

ABSTRACT

Although intravesical Bacillus Calmette-Guérin (BCG) instillation is the standard treatment for carcinoma in situ of the bladder, it is generally contraindicated in immunocompromised patients. Here we report the first case, to our knowledge, of BCG treatment for a bladder cancer patient who had received umbilical cord blood stem cell transplantation (UCBSCT). BCG can be given safely and effectively in select cases where reconstitution of the immune system has been achieved at least 2 years after UCBSCT.

Assuntos

Adjuvantes Imunológicos/administração & dosagem; Vacina BCG/administração & dosagem; Carcinoma in Situ/tratamento farmacológico; Transplante de Células-Tronco de Sangue do Cordão Umbilical; Síndromes Mielodisplásicas/terapia; Neoplasias da Bexiga Urinária/tratamento farmacológico; Adjuvantes Imunológicos/efeitos adversos; Administração Intravesical; Antineoplásicos/administração & dosagem; Vacina BCG/efeitos adversos; Vacina BCG/imunologia; Carcinoma in Situ/diagnóstico por imagem; Carcinoma in Situ/imunologia; Carcinoma in Situ/patologia; Quimiorradioterapia/efeitos adversos; Quimiorradioterapia/métodos; Cistoscopia; Esquema de Medicação; Humanos; Masculino; Pessoa de Meia-Idade; Síndromes Mielodisplásicas/imunologia; Fatores de Tempo; Condicionamento Pré-Transplante/efeitos adversos; Condicionamento Pré-Transplante/métodos; Resultado do Tratamento; Bexiga Urinária/diagnóstico por imagem; Bexiga Urinária/imunologia; Bexiga Urinária/patologia; Neoplasias da Bexiga Urinária/diagnóstico por imagem; Neoplasias da Bexiga Urinária/imunologia; Neoplasias da Bexiga Urinária/patologia

Palavras-chave

BCG; bladder cancer; carcinoma in situ; hematopoietic stem cell transplantation; umbilical cord blood stem cell transplantation

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Síndromes Mielodisplásicas / Vacina BCG / Carcinoma in Situ / Adjuvantes Imunológicos / Transplante de Células-Tronco de Sangue do Cordão Umbilical Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google